Last update Sept. 4, 2022

Aprepitant

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Aprepitant is a neurokinin-1 receptor antagonist. It is used for the prevention and treatment of nausea and vomiting caused by chemotherapy and surgery. Oral or intravenous administration.

On latest update relevant data on breastfeeding was not found.

Its moderately high molecular weight, its high volume of distribution, and its high plasma protein binding make excretion into breast milk unlikely.

Side effects are few and usually mild.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ondansetron ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Aprepitant in other languages or writings:

Groups

Aprepitant belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Aprepitant in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 59 - 67 %
Molecular weight 534 daltons
Protein Binding 97 %
VD 1 l/Kg
pKa 6.59 -
Tmax 3 - 4 hours
T½ 9 - 13 hours

References

  1. AEMPS. Aprepitant Ficha técnica 2019 Full text (in our servers)
  2. Merck Sharp & Dohme (NZ) Ltd. Aprepitant. Drug Summary. 2014 Full text (in our servers)
  3. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006 Abstract
  4. Patel L, Lindley C. Aprepitant--a novel NK1-receptor antagonist. Expert Opin Pharmacother. 2003 Abstract

Total visits

3,892

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM